EA200700871A1 - METHODS OF NEUROPROTECTION - Google Patents
METHODS OF NEUROPROTECTIONInfo
- Publication number
- EA200700871A1 EA200700871A1 EA200700871A EA200700871A EA200700871A1 EA 200700871 A1 EA200700871 A1 EA 200700871A1 EA 200700871 A EA200700871 A EA 200700871A EA 200700871 A EA200700871 A EA 200700871A EA 200700871 A1 EA200700871 A1 EA 200700871A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- group
- phenyl
- alkyl
- moreover
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Изобретение направлено на обеспечение нейропротекции, включающей введение пациенту терапевтически эффективного количества соединения, выбранного из группы, состоящей из формулы (I) и формулы (II), или его фармацевтически приемлемой соли или сложного эфирав которых фенил замещен в положении Х атомами галогена числом от одного до пяти, выбранными из группы, состоящей из фтора, хлора, брома и йода; и R, R, R, R, Rи Rнезависимо выбраны из группы, состоящей из водорода и С-С-алкила; причем С-С-алкил в случае необходимости замещен фенилом (причем фенил в случае необходимости замещен заместителями, независимо выбранными из группы, состоящей из галогена, С-С-алкила, С-С-алкокси, амино, нитро и циано).The invention is directed to providing neuroprotection, comprising administering to a patient a therapeutically effective amount of a compound selected from the group consisting of formula (I) and formula (II), or a pharmaceutically acceptable salt or ester thereof, of which phenyl is substituted at position X with halogen atoms from one to five selected from the group consisting of fluorine, chlorine, bromine and iodine; and R, R, R, R, R, and R are independently selected from the group consisting of hydrogen and C — C alkyl; moreover, C-C-alkyl is optionally substituted with phenyl (moreover, phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C-C-alkyl, C-C-alkoxy, amino, nitro and cyano).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61940204P | 2004-10-15 | 2004-10-15 | |
US69840305P | 2005-07-12 | 2005-07-12 | |
PCT/US2005/036695 WO2006044472A1 (en) | 2004-10-15 | 2005-10-14 | Carbamate compounds for use in treating neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200700871A1 true EA200700871A1 (en) | 2007-10-26 |
Family
ID=35840528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200700871A EA200700871A1 (en) | 2004-10-15 | 2005-10-14 | METHODS OF NEUROPROTECTION |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1802294A1 (en) |
JP (1) | JP2008516961A (en) |
KR (3) | KR20090130175A (en) |
AU (1) | AU2005295787A1 (en) |
BR (1) | BRPI0516112A (en) |
CA (1) | CA2584854A1 (en) |
EA (1) | EA200700871A1 (en) |
EC (1) | ECSP077395A (en) |
IL (1) | IL182432A0 (en) |
MX (1) | MX2007004491A (en) |
NI (1) | NI200700094A (en) |
NO (1) | NO20072444L (en) |
SG (1) | SG142306A1 (en) |
WO (1) | WO2006044472A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
KR20190081385A (en) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | Composition for preventing the ischemia stroke disease containing oxcarbazepine |
CN115996905A (en) | 2020-08-31 | 2023-04-21 | 生物药品解决方案有限公司 | Phenylalkyl carbamate compounds for use in preventing or treating neurodegenerative diseases |
EP4211125A1 (en) | 2020-09-10 | 2023-07-19 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
US20010034365A1 (en) * | 1996-01-16 | 2001-10-25 | Choi Yong Moon | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
CZ2002524A3 (en) * | 1999-08-20 | 2002-11-13 | Ortho-Mcneil Pharmaceutical, Inc. | Composition containing tramadol and anticonvulsants |
HUP0303264A3 (en) * | 2001-02-27 | 2012-07-30 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing and treating neurodegenerative disorders |
NZ553813A (en) * | 2004-09-16 | 2010-09-30 | Janssen Pharmaceutica Nv | Use of 2-phenyl-1, 2-ethanediol-(DI) carbamates for treating epileptogenesis and epilepsy |
-
2005
- 2005-10-14 CA CA002584854A patent/CA2584854A1/en not_active Abandoned
- 2005-10-14 EP EP05810159A patent/EP1802294A1/en not_active Withdrawn
- 2005-10-14 AU AU2005295787A patent/AU2005295787A1/en not_active Abandoned
- 2005-10-14 BR BRPI0516112-6A patent/BRPI0516112A/en not_active IP Right Cessation
- 2005-10-14 NI NI200700094A patent/NI200700094A/en unknown
- 2005-10-14 KR KR1020097019737A patent/KR20090130175A/en active Search and Examination
- 2005-10-14 MX MX2007004491A patent/MX2007004491A/en unknown
- 2005-10-14 WO PCT/US2005/036695 patent/WO2006044472A1/en active Application Filing
- 2005-10-14 EA EA200700871A patent/EA200700871A1/en unknown
- 2005-10-14 JP JP2007536843A patent/JP2008516961A/en active Pending
- 2005-10-14 KR KR1020077010744A patent/KR20070085309A/en active Application Filing
- 2005-10-14 SG SG200802877-1A patent/SG142306A1/en unknown
- 2005-10-14 KR KR1020117007395A patent/KR20110049901A/en not_active Application Discontinuation
-
2007
- 2007-04-10 IL IL182432A patent/IL182432A0/en unknown
- 2007-04-13 EC EC2007007395A patent/ECSP077395A/en unknown
- 2007-05-11 NO NO20072444A patent/NO20072444L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20070085309A (en) | 2007-08-27 |
MX2007004491A (en) | 2007-08-08 |
SG142306A1 (en) | 2008-05-28 |
WO2006044472A1 (en) | 2006-04-27 |
BRPI0516112A (en) | 2008-08-26 |
ECSP077395A (en) | 2007-05-30 |
AU2005295787A1 (en) | 2006-04-27 |
JP2008516961A (en) | 2008-05-22 |
KR20090130175A (en) | 2009-12-18 |
IL182432A0 (en) | 2007-09-20 |
KR20110049901A (en) | 2011-05-12 |
EP1802294A1 (en) | 2007-07-04 |
NO20072444L (en) | 2007-06-14 |
CA2584854A1 (en) | 2006-04-27 |
NI200700094A (en) | 2008-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200800294A1 (en) | METHODS OF NEUROPROTECTION | |
NO20071921L (en) | Methods for treating epileptogenesis and epilepsy | |
EA200701536A1 (en) | WAYS OF QT INTERVAL CONTROL | |
CY1106924T1 (en) | CARBAMIC UNITS FOR USE IN THE PREVENTION OR TRAFFICKING OF MOVEMENT DISORDERS | |
NO20080877L (en) | Methods for treating substance-related disorders | |
EA200700871A1 (en) | METHODS OF NEUROPROTECTION | |
NO20080739L (en) | Methods for Treating Epileptogenesis | |
IL157590A0 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
ATE378046T1 (en) | CARBAMAT COMPOUNDS FOR PREVENTING OR TREATING BIPOLAR DISEASES | |
RS67603A (en) | Carbamate compounds for use in the treatment of pain | |
MX2009004553A (en) | Methods for treatment of cochlear and vestibular disorders. | |
RS67503A (en) | Carbamate compounds for use in preventing of treating psychotic disorders | |
CY1110672T1 (en) | USE OF 2- FENYL-1,2-ETHANODIOL- (DI) CARBAMIC FOR SELECTION THERAPY | |
TW200701978A (en) | Methods of treating epileptogenesis and epilepsy | |
MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders |